Goldman upgrades Five Below, sees 18% rally ahead as vaccine rolls out

Share
Joel Anderson, CEO, Five Below 
Scott Mlyn | CNBC

(This story is for CNBC Pro subscribers only.)

Goldman Sachs is bullish on Five Below as a Covid-19 vaccine should be a catalyst for cyclical outperformance.

The Wall Street firm upgraded shares of Five Below to buy from neutral with a $194 per share price target, implying 18% upside from the discount retailers current levels.

More In Street Calls

CNBC ProClean energy had a record year — here are Morgan Stanley's picks going forward
CNBC ProJPMorgan strategist Kolanovic, who nailed 2020 market, increases commodities bet as inflation hedge
CNBC ProHere are Friday's biggest analyst calls of the day: Apple, Spotify, Zoom, Snap, Tesla & more